This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Biomaterials and Implants  • Dermatology  • Wound Healing  • Alert me on articles by topic

Arch Facial Plast Surg. 2005;7:170-171.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Efforts to modify the wound-healing process have led to renewed interest in growth factors in plastic surgery. By manipulating the local wound environment, it may be possible to improve the wound-healing process as desired for different clinical states.¹ This interest has spawned a generation of several commercially available systems that use autologous proteins. For background, the major growth factors that have a direct effect on the growth of fibroblasts (the main effector cell in wound healing) are fibroblast growth factor, transforming growth factor , and platelet-derived growth factor. The major growth factors that have an angiogenic effect are vascular endothelial growth factor and cysteine-rich protein 61.² Cysteine-rich protein 61, which is a heparin-binding, extracellular matrix–associated protein, is a signaling molecule with functions in cell migration, adhesion, and proliferation.

In an excellent article that appears in this issue of the ARCHIVES, Sclafani et al³ report that treatment with platelet . . . [Full Text of this Article]

AUTHOR INFORMATION
R. James Koch, MD

RELATED ARTICLE

Modulation of Wound Response and Soft Tissue Ingrowth in Synthetic and Allogeneic Implants With Platelet Concentrate
Anthony P. Sclafani, Thomas Romo, III, Gennady Ukrainsky, Steven A. McCormick, Jason Litner, Sherwin V. Kevy, and May S. Jacobson
Arch Facial Plast Surg. 2005;7(3):163-169.
ABSTRACT | FULL TEXT